Intuitive Surgical makes robotic systems that help surgeons operate through tiny cuts instead of large ones. The flagship product is the da Vinci surgical system, a robot that a surgeon controls from a seated console while mechanical arms hold instruments inside the patient's body. Hospitals pay roughly $1.5 to $1.75 million to buy a da Vinci system. Then, every single procedure that runs on that system requires fresh instruments and accessories that can only be used a set number of times before they must be replaced. That consumables stream, not the hardware sale, is where most of the money flows. The diagram below traces where the money goes.
How Intuitive Surgical Makes Money
flowchart LR
A["Surgeon Console<br/>Patient-Side Cart<br/>Vision System"] --> B["da Vinci Systems<br/>2.5B revenue"]
C["Stapling Instruments<br/>Energy Products<br/>Vessel Sealers"] --> D["Instruments &<br/>Accessories<br/>6.0B revenue"]
B --> E["Hospital Adoption<br/>& Procedure Volume"]
D --> E
E --> F["Service Plans<br/>Maintenance<br/>Support<br/>1.6B revenue"]
F --> G["Customer Data<br/>Connected Systems"]
G --> H["Digital Solutions<br/>My Intuitive<br/>Case Insights"]
H --> I["Training Pathways<br/>SimNow<br/>Learning Platform"]
I --> E
H --> E
F --> B
F --> D
Five years of financial data show a business growing steadily in one direction. Revenue climbed from $5.7 billion in 2021 to $10.1 billion in 2025, a near-doubling over four years. Operating cash flow moved in step, rising from $2.1 billion to $3.0 billion over the same period. The company holds no net debt. In fact, the net debt figure is deeply negative, meaning Intuitive holds far more cash and investments than it owes. As of the end of 2025, it held $9.03 billion in cash, equivalents, and investments.
Annual Revenue (2021 to 2025)
Revenue in billions of dollars. Source: XBRL filings.
The engine behind that revenue growth is procedure volume. Approximately 3,153,000 da Vinci procedures were performed in 2025, up 18% from the year before. Each procedure consumes instruments and accessories that hospitals must repurchase. More procedures mean more consumable revenue, and consumable revenue reached $6.02 billion in 2025 alone. Systems revenue added another $2.47 billion as 1,721 new da Vinci systems were placed during the year, bringing the total installed base to roughly 11,106 systems worldwide.
$6.02B
Instruments and accessories revenue in 2025, the consumables engine that refills automatically with every procedure
Gross margin tells a more nuanced story. It sat at 69.3% in 2021 and slipped to 66.0% in 2025. That is still a healthy margin, but the direction matters. Tariffs are one clear cause. In 2025, tariffs and trade measures added approximately $63 million to cost of revenues. Most instruments and accessories are manufactured in Mexicali, Mexico, and endoscopes come from Germany. Both supply lines now carry tariff pressure that did not exist a few years ago.
What is gross margin?
Gross margin is the percentage of revenue left after paying the direct costs of making a product. A company with 66% gross margin keeps 66 cents from every dollar of sales before paying for things like marketing, research, and office costs. A falling gross margin means making each product is becoming more expensive relative to the price charged.
Margin has compressed over five years, with tariffs contributing roughly $63 million in additional cost in 2025 alone.
Beyond tariffs, Intuitive faces several specific threats worth naming clearly. Weight loss drugs approved by the FDA have reduced the number of bariatric surgeries performed using da Vinci systems. Bariatric procedures are one of the system's established use cases, so a sustained drop in those surgeries removes a real source of consumable volume. The long-term impact of these drugs on demand is, by the company's own admission, unpredictable.
China adds a separate layer of risk. An anti-corruption campaign targeting the healthcare sector that launched in July 2023 caused hospital purchasing tenders to be canceled or delayed with no clear timeline. In 2025, that campaign combined with local competition to push system placements in China below expectations. China also announced export controls on rare earth elements that are critical to components used in Intuitive's products. If those controls tighten, sourcing alternatives for certain materials could prove difficult.
162
Da Vinci systems placed in China under the government's 559-unit quota as of December 31, 2025, out of a pool open to multiple competing companies
What is a usage-based lease?
Instead of selling a system outright, Intuitive sometimes lets hospitals pay based on how many procedures they actually perform. This is called a usage-based lease. If the hospital uses the robot less than expected, Intuitive collects less money. If a hospital stops using the system and returns it before it is fully paid off, Intuitive can take a loss on that equipment.
The company is expanding its usage-based lease arrangements, which shifts some financial risk onto Intuitive itself. If hospitals use systems less than expected, revenue falls short. Returned systems that are not fully depreciated generate losses. This model works well when procedure volumes keep climbing, but it becomes a problem if volume growth slows or reverses.
2024
milestone
Da Vinci 5 Launches
In March 2024, the FDA cleared the fifth-generation da Vinci 5 surgical system. It carries more than 10,000 times the computing power of its predecessor, adds force feedback so surgeons can sense pressure on tissue, and integrates digital tools including a virtual reality simulator and real-time case analytics. By December 31, 2025, 1,231 da Vinci 5 systems had been placed. The new platform also introduced a digital subscription package called My Intuitive Plus, adding a recurring software revenue stream on top of existing consumables and service revenue.
The Ion endoluminal system is the company's second major platform. It is a flexible robotic catheter that navigates deep into the lung to perform biopsies of suspicious nodules that are hard to reach by other means. Ion procedures reached approximately 144,100 in 2025, up 51% from the year before. The installed base grew to roughly 995 Ion systems. Ion is still small relative to da Vinci, but its growth rate is notable, and in October 2025, the FDA cleared software that adds artificial intelligence across Ion's entire navigational workflow.
Lawsuits brought by hospitals and repair companies since 2021 allege that Intuitive charges too much for replacement parts and uses its market position to block competitors. These cases are ongoing. The company also paid $43 million in 2018 to settle a shareholder lawsuit over injury reporting. Neither set of claims has materially disrupted financial results so far, but they reflect friction between Intuitive's market dominance and the preferences of the hospitals it depends on.
18%
Growth in da Vinci procedures in 2025, the metric that directly drives consumable revenue
The Bet
Robotic surgery keeps expanding into new procedures and new hospitals fast enough to offset the specific headwinds that are already visible. Weight loss drugs may shrink bariatric volume. China's anti-corruption campaign and local competition may permanently reduce what was once a high-growth market. Tariffs may keep squeezing margins. The consumables model only compounds if the installed base keeps growing and utilization per system keeps rising. If procedure volume growth slows materially, the revenue engine slows with it, and the usage-based leases that are replacing upfront system sales mean the financial impact of any slowdown arrives faster than it would have under the old model.
Open question
Intuitive's business has produced consistent revenue growth, deep cash generation, and a no-net-debt balance sheet. The da Vinci 5 is winning early adoption, Ion is growing fast, and the installed base of over 11,000 systems keeps generating consumable revenue with every procedure. At the same time, gross margins are drifting lower, tariff costs are rising, China is uncertain, weight loss drugs are reshaping one of the core procedure categories, and the shift toward usage-based leases means the company takes on more risk if volume disappoints. Can procedure volume grow fast enough across enough new procedures and geographies to outrun the combined pressure of tariffs, drug-driven demand shifts, and a Chinese market that may never return to its earlier trajectory?
Compiled · 10-K · FY2025
